key papersKey paper

The Repurposing Drugs in Oncology (ReDO) Project

Paper cited by one bottleneck page and 21 idea pages, indexed on Europe PMC as PubMed record 25075216 and published in Ecancermedicalscience; the citing pages link this DOI, which is how the record was matched.

The Repurposing Drugs in Oncology (ReDO) Project seeks to repurpose well-known and well-characterised non-cancer drugs for new uses in oncology. The rationale for this project is presented, examining current issues in oncological drug development, challenges for health systems, and existing and future patient needs. In addition to discussing the advantages of repurposing, the paper also outlines some of the characteristics used in the selection of drug candidates by this project. Challenges in moving candidate drugs into clinical trial and subsequent practice are also discussed.

Indexed on Europe PMC as PubMed record 25075216 (DOI 10.3332/ecancer.2014.442). Matched by DOI alone: one bottleneck page and 21 idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

Observational study139 citations

Authors

Pantziarka P, Bouche G, Meheus L, et al.

Published

Ecancermedicalscience, 2014

Full text

doi:10.3332/ecancer.2014.442 PubMed 25075216

What it means

One bottleneck page and 21 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Caveats

Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

Connected

22top

ideas

A $50 million prize for the first off-patent drug proven to extend cancer survival A biomarker-directed trial of vitamin D after surgery for digestive tract cancers A delinked market-entry reward paid by payers when a repurposed generic wins approval A DRUP-style protocol for off-label generic targeted drugs in rare tumours A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer A non-profit company to hold marketing authorisations for repurposed cancer drugs A pragmatic trial of statins to prevent liver cancer in people with cirrhosis A public fund and label pathway to trial generic drugs against cancer A social impact bond: investors fund a repurposing trial, payers repay from savings A strategic reserve of essential generic cancer drugs to end recurring shortages Add a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial An automated pipeline emulating trials of every common drug against every cancer Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3 Payers pre-commit to cover off-label generics when a definitive trial is positive Perioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery Pre-registered, publicly scored AI ranking of repurposing candidates for cancer Randomise a cheap antihistamine alongside immunotherapy Require genetic and target-trial evidence before funding any repurposing phase 3 Three years of indication-specific exclusivity for proving a new cancer use of an old drug Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines

bottlenecks

No incentive to repurpose cheap drugs

The Repurposing Drugs in Oncology (ReDO) Project

Overview

Connected

Similar pages

ideas

bottlenecks